Targeted cancer therapies are becoming increasingly important in combination with conventional therapies / cytostatics. PHARMALINK took early account of the growing importance of the novel drugs and adapted the content of its surveys in haematologists / oncologists with the first substances. One focus is u.a. in the field of passive immunotherapies with antibodies. In addition, PHARMALINK has many years of experience in the field of anti-hormone therapy of oncology practicing urologists and gynaecologists.